Tvardi Therapeutics, Inc. 8-K

What Happened
On May 8, 2026, Tvardi Therapeutics, Inc. issued a press release announcing its financial results and business highlights for the fiscal quarter ended March 31, 2026. The press release dated May 8, 2026 is attached to the company’s Form 8-K as Exhibit 99.1 and the information is furnished under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Press release announcing quarterly results and business highlights dated May 8, 2026.
• Covers performance for the fiscal quarter ended March 31, 2026.
• Information furnished to the SEC under Item 2.02 of Form 8-K (not filed).
• Inline XBRL cover page (Interactive Data File) is included with the filing.

Why It Matters
This 8-K notifies investors that Tvardi released its latest quarterly financial and operational update—material information that may affect valuation and trading. The filing itself furnishes the press release but does not replace full financial statements; investors should read Exhibit 99.1 for the company’s reported revenue, expenses, cash position, and any clinical or corporate milestones disclosed. Review the press release and subsequent filings for the detailed numbers and context before making investment decisions.